Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Cash & Equivalents (2016 - 2026)

Apyx Medical filings provide 16 years of Cash & Equivalents readings, the most recent being $31.7 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents changed 0.13% to $31.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.7 million, a 0.13% change, with the full-year FY2025 number at $31.7 million, changed 0.13% from a year prior.
  • Cash & Equivalents hit $31.7 million in Q4 2025 for Apyx Medical, up from $25.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $43.7 million in Q4 2023 to a low of $10.2 million in Q4 2022.
  • Median Cash & Equivalents over the past 5 years was $30.1 million (2021), compared with a mean of $27.7 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 66.98% in 2022 and later surged 328.3% in 2023.
  • Apyx Medical's Cash & Equivalents stood at $30.9 million in 2021, then tumbled by 66.98% to $10.2 million in 2022, then surged by 328.3% to $43.7 million in 2023, then dropped by 27.29% to $31.7 million in 2024, then dropped by 0.13% to $31.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $31.7 million (Q4 2025), $25.1 million (Q3 2025), and $29.3 million (Q2 2025) per Business Quant data.